Programmable
A modular design intended to address distinct targets through sequence-specific recognition.
Programmable epigenetic medicines
Restoring function.
Preserving possibility.
Epivida is advancing compact, programmable medicines designed to address the molecular drivers of muscle dysfunction.
Target-definedPrograms built around measurable biology
Function-ledDesigned with muscle performance in view
Precision at the locusDesigned for selective gene regulation
OUR MISSION
Translate precise control of gene expression into meaningful improvements in human function.
PNAFUSE™ PLATFORM
A compact architecture for programmable gene regulation.
PNAfuse combines a sequence-directed PNA component with an effector designed to influence gene activity at a selected locus—without cutting DNA.
- 01Compact cargo
A modular PNA–effector construct is designed for delivery to muscle.
- 02Nuclear access
The construct is intended to reach the nucleus, where gene regulation occurs.
- 03Locus recognition
Sequence-directed binding is designed to localize activity to a selected site.
- 04Effector recruitment
A linked effector is intended to tune local chromatin and gene expression.
Compact
A small nucleic-acid architecture designed to support practical delivery development.
Non-cutting
Built to regulate gene activity without introducing permanent DNA breaks.
Redosing-oriented
Designed with repeat administration in mind; feasibility remains to be established.
PIPELINE
Two programs focused on muscle function.
Our programs apply the PNAfuse architecture to genetically and biologically defined drivers of muscle dysfunction.
LEAD PROGRAMEPH-101
FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
Silencing the DUX4 disease program in FSHD muscle.
A locus-directed program intended to repress pathogenic DUX4 expression and support restoration of muscle function.
FOLLOW-ON PROGRAMEPH-102
MOBILITY DISABILITY
Preserving the muscle function that supports independent movement.
A programmable epigenetic medicine program designed to address age-associated pathways linked to muscle performance and mobility.
All programs are preclinical. Development candidates have not been nominated, and safety or efficacy has not been established.
BUILT FOR DECISIVE LEARNING
Evidence first. Platform value follows.
Epivida’s development strategy is organized around clear, measurable gates—from target engagement through gene regulation and muscle function.
Start a conversation →01Target engagementConfirm site-specific binding
02Gene regulationMeasure intended molecular effect
03Functional responseAssess relevant muscle endpoints
04Delivery & durabilityDefine exposure and persistence
CONNECT WITH EPIVIDA
Advancing a new generation of programmable muscle medicines.
We welcome conversations with scientific collaborators, development partners, and investors.
David.OHagan@epividabio.com ↗